A United Arab Emirates company, Group42 or G42, is nearing the end of phase 3 clinical trials for a Chinese COVID-19 vaccine. They are hoping to start producing in the masses next year. This potential vaccine was a product of the partnership between G42, an Abu-Dhabi based AI firm, and Sinopharm’s China National Biotech Group. The vaccine uses traditional tactics including administering dead or inactivated virus cells into the host, a strategy used to treat many past pandemics. It has been said that their plan is to produce and distribute 75-100 million doses next year in the UAE.

Read more here.

More on: